{
  "Country": "PO",
  "PICOs": [
    {
      "Population": "Patients with lung cancer (ICD - 10: C34) and pleural mesothelioma (ICD - 10: C45)",
      "Intervention": "Sotorasib (Lumykras)",
      "Comparator": "Docetaxel, Nintedanib",
      "Outcomes": "Progression-free survival (PFS), Overall response rate (ORR), Quality of life (QoL)"
    },
    {
      "Population": "Immunotherapy-na√Øve patients with lung cancer",
      "Intervention": "Atezolizumab or Nivolumab",
      "Comparator": "Standard of care (chemotherapy, EGFR inhibitors, ALK inhibitors)",
      "Outcomes": "Efficacy and safety outcomes, Quality of life (QoL)"
    }
  ]
}